In a recent study by Yoshitake et al., the efficacy of anti-cancer therapy was assessed by administering a vaccine containing a mixture of three TAA peptides (LY6K, CDCA1, and IMP-3) to patients with head and neck squamous cell cancer [31]. This evidence concerns the gene LY6K and cancer.